• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Methylcobalamin

Background

Methylcobalamin is the biologically active form of vitamin B12 and is used in Japan to treat peripheral neuropathy and megaloblastic anaemia. Methylcobalamin has the ability to decrease levels of homocysteine, a molecule that can contribute to neuronal degeneration which led to it being considered as a potential candidate for ALS/MND treatment.

Based on some small early-stage human studies, a Japanese pharmaceutical company, Eisai, supported a Phase II/III clinical trial.

This trial was run between 2007 and 2014 in 51 sites in Japan with 360 participants. The treatment regime was quite long (3.5 years), with participants receiving placebo, or 25 or 50mg methylcobalamin twice a week via intramuscular injections. Results from this initial trial showed that receiving methylcobalamin did not lead to any significant differences either in survival rates or ALS/MND functional scores, when compared with placebo.

However, subsequent analysis of the data showed that methylcobalamin seemed to have an effect in a sub-group of participants who received treatment earlier in their disease journey (a year or less after symptom onset). These participants showed a statistically significant decrease in the rate of disease progression (i.e., a decrease in the rate of decline of the ALSFRS-R score), and also survived longer or took longer to require ventilation support compared with the placebo group. The outcome of the trial was published in January 2019 (“Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study”).

However, this data was not considered sufficient for approval as an ALS/MND treatment by the Japanese authorities because it was done after the initial study results were obtained (post-hoc analysis) and such observations can be misleading.

In an attempt to validate the post-hoc findings, a new Phase 3 trial, JETALS, was undertaken in 2017, which focused on participants who seemed to respond well to the treatment from the first trial, i.e. those whose symptoms had begun within one year of enrollment and who progressed at a moderate rate (defined as a 1–2 point decrease in their ALSFRS-R scores over the three months preceding the trial).

Trial Design & Results

Participants received twice-weekly injections of either 50 mg of methylcobalamin or a placebo for 16 weeks. An open-label extension was then made available to all trial participants in which they will receive the therapy until March 2024.

The initial 16-week trial met its primary outcome, with methylcobalamin-treated participants showing a 43% slower disease progression as measured by their ALSFRSR scores than those given a placebo (2.66 vs. 4.63 points over 16-weeks). Participants receiving Riluzole as well as methylcobalamin showed similar results. There was no difference in side effects of the drug between placebo or methylcobalamin-treated participants. Although there were statistically significant reductions in ALSFRS-R, other measures such as muscle strength, forced vital capacity and the ALSAQ-40 total score, were not changed.

The results from this trial were published in May 2022: “Efficacy and Safety of Ultra-high-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis A Randomized Clinical Trial.”

There are several things to take into account for this study. As the drug was only tested on participants early in the disease process, it is not clear if the treatment would be appropriate for participants with more advanced disease. Methylcobalamin treatment results in a marked change in urine colour which could mean that participants may have known whether they were receiving placebo or methylcobalamin and that could influence results (including a potential “nocebo” effect). The fact that the placebo group appeared to worsen their rate of disease progression once the trial commenced perhaps supports these concerns of a potential unblinding effect. The open label extension data may well help to offset any possible confounding effects. It should be considered that the 16-week trial duration is shorter than most other trials which usually have a minimum 24-week duration.

Data from the open-label extension will be informative for the longer-term benefits of this drug.

Summary

The Scientific Advisory Council (SAC) believes that the initial trial and follow-up stage 3 trial have demonstrated promising results in a subset of early stage participants. The company have stated they will file for approval from the Japanese authorities in 2023. Due to the short trial duration and potential confounding effects (hastened placebo decline, possible unblinding), it is difficult at this time to know the true efficacy, if any, of ultra high-dose methylcobalamin in ALS/MND and any consideration of use should be at a clinician’s discretion. The SAC suggests that data from the open label extension be incorporated into analysis to better assess the efficacy of this treatment.

International Alliance of ALS/MND Associations
March 2023


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

 

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • T Regulatory Cell Therapies
  • Ulefnersen – Ionis Pharmaceuticals

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Liam Dwyer, England

    Liam Dwyer, England

  • Daniel Hare

    Daniel Hare

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Peng Yi-Wen

    Peng Yi-Wen

  • Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

  • Maria Santos Garcia Tellez, Diagnosed 2017 , FYADENMAC, Mexico

    Maria Santos Garcia Tellez, Diagnosed 2017 , FYADENMAC, Mexico

  • Monica Soriano, Diagnosed 2011 ,  Asociación ELA , Argentina

    Monica Soriano, Diagnosed 2011 , Asociación ELA , Argentina

  • Marcel R. Wernard, Diagnosed 2016,  ALS Patients Connected,  The Netherlands

    Marcel R. Wernard, Diagnosed 2016, ALS Patients Connected, The Netherlands

  • Bob Simonds and Drew O'Neil, USA

    Bob Simonds and Drew O’Neil, USA

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

    Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

  • Ali Var, Turkey

    Ali Var, Turkey

  • Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

  • David Watson,  MND Scotland,  Diagnosed 2018

    David Watson, MND Scotland, Diagnosed 2018

  • Wilfried Leusing

    Wilfried Leusing

  • Wendy Hendrickson, ALS Hope Foundation, USA

    Wendy Hendrickson, ALS Hope Foundation, USA

  • Jan Zuring, Diagnosed 2010 , The Netherlands

    Jan Zuring, Diagnosed 2010 , The Netherlands

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

    Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

  • Len Johnrose,  MND Association,  Diagnosed 2017,  England

    Len Johnrose, MND Association, Diagnosed 2017, England

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • Kirsty Gerlach, MND New Zealand, Diagnosed 2017

    Kirsty Gerlach, MND New Zealand, Diagnosed 2017

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

    Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

  • Erwin Coppejans, Diagnosed 2007 , ALS Liga België, Belgium

    Erwin Coppejans, Diagnosed 2007 , ALS Liga België, Belgium

  • Jorge Melo, ABrELA, Brazil

    Jorge Melo, ABrELA, Brazil

  • Ada Garrido Benavidez, Diagnosed 2016,  FYADENMAC, Mexico

    Ada Garrido Benavidez, Diagnosed 2016, FYADENMAC, Mexico

  • Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

  • Nicholas (Nic) Bowman, MND Association of South Africa,  Diagnosed 2016,  Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • JP

    JP

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Mary Thomas, Diagnosed 2013 , MND Australia

    Mary Thomas, Diagnosed 2013 , MND Australia

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • 393647_2252248542053_984912751_n

    393647_2252248542053_984912751_n

  • Ann Nicol

    Ann Nicol

  • Steven Spencer, Diagnosed 2014 , MND New Zealand

    Steven Spencer, Diagnosed 2014 , MND New Zealand

  • Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

    Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Timmy, ALS Liga

    Timmy, ALS Liga

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Bjarne Hytjanstorp, ALS Norge, Norway

    Bjarne Hytjanstorp, ALS Norge, Norway

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login